PAMAM Dendrimers Functionalised with an Anti-TNF α Antibody and Chondroitin Sulphate for Treatment of Rheumatoid Arthritis

last updated: 2021-01-15
ProjectTERM - Programa Doutoramento Norte 2020 :: publications list
TitlePAMAM Dendrimers Functionalised with an Anti-TNF α Antibody and Chondroitin Sulphate for Treatment of Rheumatoid Arthritis
Publication TypePapers in Scientific Journals
Year of Publication2021
AuthorsOliveira I. M., Cristiana G., Oliveira E. P., Rosana S. - V., Silva A. M., África G. - F., Reis R. L., and Dr. Oliveira J. M.
Abstract

Rheumatoid arthritis is a chronic autoimmune disease characterised by joint synovial inflammation, along with cartilage and bone tissue destruction. Dendrimers can offer new opportunities as drug delivery systems of molecules of interest. Herein we aimed to develop poly(amidoamine) dendrimers (PAMAM), functionalised with chondroitin sulphate (CS), lined with anti-TNF α antibodies (Abs) to provide anti-inflammatory properties. Physicochemical characterisation demonstrated that anti-TNFα Abs-CS/PAMAM dendrimer NPs were successfully produced. The in vitro studies revealed that CS/PAMAM dendrimer NPs did not affect the ATDC5 and THP-1 cell lines’ metabolic activity and proliferation, presenting good cytocompatibility and hemocompatibility. Moreover, anti-TNFα Abs-CS/PAMAM dendrimer NPs showed suitable TNF α capture capacity, making them appealing for new immunotherapies in RA patients.

JournalMaterials Science and Engineering: C
Pagination111845
Date Published2021-01-06
PublisherElsevier
ISSN0928-4931
DOI10.1016/j.msec.2020.111845
URLhttps://www.sciencedirect.com/science/article/pii/S0928493120337644?via%3Dihub
KeywordsAnti-TNF α, Chondroitin sulphate, inflamed joint, PAMAM dendrimer, Polyclonal antibody, rheumatoid arthritis
RightsopenAccess
Peer reviewedyes
Statuspublished

Back to top